Table 1: Patient and tumor characteristics (N=83).
Male Mean age (years) |
25 64.9 ± 12.8 |
M.D. Anderson Stage (modified) [7] III AB III (B)A IV |
34 31 11 7 |
Primary tumor localization Below the knee/elbow Above the knee/elbow No primary tumor Highest ITM localization before ILP Below the knee/elbow Above the knee/elbow Median number of ITM in time period before ILP |
70 5 8
46 37 8 (IQR 4 – 20) |
Median time diagnosis primary to ILP (months) |
25.7 (IQR 10 – 65) |
Number of previous relapses Median time between relapses (months) SNB No |
2 (IQR 1 – 3) 11.5 (IQR 7 – 19)
20 63 |
LND before ILP Yes Positive Negative ELND |
30 24 6 5 1 1 9 6 |
LND at moment ILP |
|
Yes Positive |
70 31 9 2 8 12 39 |
Clark level primary malignant melanoma 2 – 3 4 – 5 Median Breslow (mm) Male 3.4 (IQR 2 – 5) – female 2.4 (IQR 2 – 4) |
9 57 2.8 (IQR 2 – 4) |
Subtype Acral lentiginous (median breslow 2 mm (IQR 1.6 – 6.2)) Superficial spreading (median breslow 2.25 mm (IQR 1.9 – 3.5)) Nodular (median breslow 3.5 mm (IQR 2.2 – 4.0)) Ulceration |
11 30 26 |
Yes No Mitotic index (/mm²) ≤ 6 > 6 Lymphovascular invasion Yes No |
36 30
27 28
55 43 |
N: number of patients; ILP: isolated limb perfusion; ITM: in-transit metastases; SNB: sentinel node biopsy; LND: lymph node dissection; CLND: completion lymph node dissection; ELND: elective lymph node dissection.
Mean values reported with standard deviation; IQR: interquartile range.
Stage III(B)A: patients with a positive LND at least three months before their ILP, who presented at time of perfusion with ITM without nodal recurrence.